A few most common cancer types include lung cancer, breast cancer, colon cancer, rectum cancer, and prostate cancer. The condition develops in ~400,000 children every year. Carcinogenic infections, including Helicobacter pylori, hepatitis B virus, human papillomavirus (HPV), hepatitis C virus, and Epstein-Barr virus, caused ~13% of cancer cases in 2018 regionally. The International Agency for Research on Cancer (IARC) projects that the number of new cancer cases and cancer-related deaths worldwide would grow ~1.6–1.7 fold to reach 29.5 million by 2040 from 16.4 million in 2018. Further, according to the American Society of Clinical Oncology, in 2021, ~290,560 people (287,850 women and 2,710 men) in the US were diagnosed with invasive breast cancer. Breast cancer in females has now surpassed lung cancer as the most commonly diagnosed cancer worldwide. ~2,261,419 women were diagnosed with breast cancer in 2020.
All the observations recorded about cancer in the US over the past several decades show that metastatic cancer accounts for up to 90% of all cancer deaths each year. These numbers have motivated doctors and researchers to find new ways to treat metastasis, which occurs when cancer spreads beyond its point of origin. In the US, 6% of women were diagnosed with metastatic breast cancer in the first diagnosis. Such rise in the prevalence of cancer and metastatic cancer is driving the growth of the metastatic cancer drug market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metastatic cancer drugs market growth in the coming years. The market is expected to grow at a good CAGR during the forecast period.
North America Metastatic Cancer Drugs Market Segmentation
The North America metastatic cancer drugs market is segmented on the basis of cancer type, route of administration, drug class, product, and end user. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is bifurcated into intravenous and intramuscular. Based on drug class , the North America metastatic cancer drugs market is segmented into HER2 inhibitors, immune checkpoint inhibitors, parp
inhibitors, kinase inhibitors, and others. Based on product, the market is segmented into branded, generics, and biosimilars . Based on end user, the market is segmented into hospital, specialty clinic, and others. By country, the North America metastatic cancer drugs market is segmented into the US, Mexico, and Canada.
North America Metastatic Cancer Drugs Market – Companies Mentioned
AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; Novartis AG; Astrazeneca; Eli Lilly and Company; MERCK KGaA ; Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc. are among the leading companies in the North America metastatic cancer drugs market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 21,414.73 Million |
| Market Size by 2028 | US$ 27,989.14 Million |
| CAGR (2021 - 2028) | 3.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Cancer Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Metastatic Cancer Drugs Market is valued at US$ 21,414.73 Million in 2021, it is projected to reach US$ 27,989.14 Million by 2028.
As per our report North America Metastatic Cancer Drugs Market, the market size is valued at US$ 21,414.73 Million in 2021, projecting it to reach US$ 27,989.14 Million by 2028. This translates to a CAGR of approximately 3.9% during the forecast period.
The North America Metastatic Cancer Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Metastatic Cancer Drugs Market report:
The North America Metastatic Cancer Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Metastatic Cancer Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Metastatic Cancer Drugs Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Metastatic Cancer Drugs Market
